Valuation : Rapport Therapeutics, Inc.

Market Cap 2.11B 1.81B 1.71B 1.55B 2.91B 200B 2.92B 20.22B 7.81B 102B 7.91B 7.73B 323B P/E 2026 *
-10.8x
P/E 2027 * -8.95x
Enterprise Value 1.78B 1.53B 1.44B 1.31B 2.45B 169B 2.46B 17.06B 6.59B 86.12B 6.67B 6.53B 273B EV / Sales 2026 *
88.8x
EV / Sales 2027 * -
Free-Float
96.08%
Yield 2026 *
-
Yield 2027 * -
1 day-4.78%
1 week-9.87%
Current month-9.83%
1 month-3.53%
3 months+22.45%
6 months+43.70%
Current year+44.64%
1 week 43.13
Extreme 43.13
48
1 month 43.13
Extreme 43.13
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 22.06
Extreme 22.06
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 31/12/2022
Chief Executive Officer 48 31/01/2023
Director of Finance/CFO 58 31/10/2023
Director TitleAgeSince
Director/Board Member 61 22/08/2023
Director/Board Member 48 28/02/2023
Director/Board Member 54 31/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Sell

Chief Executive Officer

-8,210 0.0171%
25/08/26 Sell

Executive/Senior Manager

-37,000 0.0774%
25/08/26 Sell

Chief Executive Officer

-18,921 0.0396%
Change 5-day change 1-year change 3-year change Capi.($)
-4.78%-9.87%+56.56% - 2.11B
+0.87%-6.98%-2.73%+11.12% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
-0.11%-3.76%+12.33%+30.49% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.02%-3.58%+68.88%+111.09% 26.91B
Weighted average by Cap. -0.35%-3.09%+85.73%+133.03%

Financials

2026 *2027 *
Net sales 20M 17.21M 16.2M 14.77M 27.63M 1.9B 27.74M 192M 74.23M 970M 75.1M 73.47M 3.07B -
Net income -194M -167M -157M -143M -268M -18.47B -269M -1.86B -720M -9.41B -729M -713M -29.81B -252M -217M -204M -186M -349M -24.02B -350M -2.42B -937M -12.24B -948M -927M -38.76B
Net Debt -329M -283M -267M -243M -455M -31.32B -456M -3.16B -1.22B -15.95B -1.24B -1.21B -50.54B -477M -410M -386M -352M -658M -45.36B -661M -4.58B -1.77B -23.11B -1.79B -1.75B -73.21B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
09/09/26 US$43.89 -4.78% 437,739
08/09/26 US$46.09 +0.70% 489,386
04/09/26 US$45.77 -3.95% 279,884
03/09/26 US$47.65 -2.14% 276,962
02/09/26 US$48.69 +0.27% 294,754
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
43.88USD
Average target price
62.05USD
Spread / Average Target
+41.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!